Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Correction: Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma.

Short SP, Barrett CW, Stengel KR, Revetta FL, Choksi YA, Coburn LA, Lintel MK, McDonough EM, Washington MK, Wilson KT, Prokhortchouk E, Chen X, Hiebert SW, Reynolds AB, Williams CS.

Oncogene. 2019 May 8. doi: 10.1038/s41388-019-0829-z. [Epub ahead of print]

PMID:
31068667
2.

Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma.

Short SP, Barrett CW, Stengel KR, Revetta FL, Choksi YA, Coburn LA, Lintel MK, McDonough EM, Washington MK, Wilson KT, Prokhortchouk E, Chen X, Hiebert SW, Reynolds AB, Williams CS.

Oncogene. 2019 Mar 11. doi: 10.1038/s41388-019-0777-7. [Epub ahead of print] Erratum in: Oncogene. 2019 May 8;:.

PMID:
30858547
3.

BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability.

Choksi YA, Reddy VK, Singh K, Barrett CW, Short SP, Parang B, Keating CE, Thompson JJ, Verriere TG, Brown RE, Piazuelo MB, Bader DM, Washington MK, Mittal MK, Brand T, Gobert AP, Coburn LA, Wilson KT, Williams CS.

Mucosal Immunol. 2018 Sep;11(5):1363-1374. doi: 10.1038/s41385-018-0043-2. Epub 2018 Jun 15.

4.

MTG16 is a tumor suppressor in colitis-associated carcinoma.

McDonough EM, Barrett CW, Parang B, Mittal MK, Smith JJ, Bradley AM, Choksi YA, Coburn LA, Short SP, Thompson JJ, Zhang B, Poindexter SV, Fischer MA, Chen X, Li J, Revetta FL, Naik R, Washington MK, Rosen MJ, Hiebert SW, Wilson KT, Williams CS.

JCI Insight. 2017 Aug 17;2(16). pii: 78210. doi: 10.1172/jci.insight.78210. eCollection 2017 Aug 17.

5.

BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.

Parang B, Kaz AM, Barrett CW, Short SP, Ning W, Keating CE, Mittal MK, Naik RD, Washington MK, Revetta FL, Smith JJ, Chen X, Wilson KT, Brand T, Bader DM, Tansey WP, Chen R, Brentnall TA, Grady WM, Williams CS.

Gut. 2017 May;66(5):852-862. doi: 10.1136/gutjnl-2015-310255. Epub 2016 Jan 14.

6.

Selenoproteins and oxidative stress-induced inflammatory tumorigenesis in the gut.

Barrett CW, Short SP, Williams CS.

Cell Mol Life Sci. 2017 Feb;74(4):607-616. doi: 10.1007/s00018-016-2339-2. Epub 2016 Aug 25. Review.

7.

Whole-mount Enteroid Proliferation Staining.

Barrett CW, Short SP, Choksi YA, Williams CS.

Bio Protoc. 2016 Jun 20;6(12). pii: e1837. doi: 10.21769/BioProtoc.1837.

8.

α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.

Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, Hastings TG, Greenamyre JT.

Sci Transl Med. 2016 Jun 8;8(342):342ra78. doi: 10.1126/scitranslmed.aaf3634.

9.

Myeloid translocation genes differentially regulate colorectal cancer programs.

Parang B, Bradley AM, Mittal MK, Short SP, Thompson JJ, Barrett CW, Naik RD, Bilotta AJ, Washington MK, Revetta FL, Smith JJ, Chen X, Wilson KT, Hiebert SW, Williams CS.

Oncogene. 2016 Dec 8;35(49):6341-6349. doi: 10.1038/onc.2016.167. Epub 2016 Jun 6.

10.

AOM/DSS Model of Colitis-Associated Cancer.

Parang B, Barrett CW, Williams CS.

Methods Mol Biol. 2016;1422:297-307. doi: 10.1007/978-1-4939-3603-8_26.

11.

BVES Regulates Intestinal Stem Cell Programs and Intestinal Crypt Viability after Radiation.

Reddy VK, Short SP, Barrett CW, Mittal MK, Keating CE, Thompson JJ, Harris EI, Revetta F, Bader DM, Brand T, Washington MK, Williams CS.

Stem Cells. 2016 Jun;34(6):1626-36. doi: 10.1002/stem.2307. Epub 2016 Mar 15.

12.

Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage.

Barrett CW, Reddy VK, Short SP, Motley AK, Lintel MK, Bradley AM, Freeman T, Vallance J, Ning W, Parang B, Poindexter SV, Fingleton B, Chen X, Washington MK, Wilson KT, Shroyer NF, Hill KE, Burk RF, Williams CS.

J Clin Invest. 2015 Jul 1;125(7):2646-60. doi: 10.1172/JCI76099. Epub 2015 Jun 8.

13.

Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis.

Barrett CW, Singh K, Motley AK, Lintel MK, Matafonova E, Bradley AM, Ning W, Poindexter SV, Parang B, Reddy VK, Chaturvedi R, Fingleton BM, Washington MK, Wilson KT, Davies SS, Hill KE, Burk RF, Williams CS.

PLoS One. 2013 Jul 4;8(7):e67845. doi: 10.1371/journal.pone.0067845. Print 2013.

14.

Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters.

Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS.

PLoS One. 2012;7(12):e51205. doi: 10.1371/journal.pone.0051205. Epub 2012 Dec 12.

15.

Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma.

Barrett CW, Ning W, Chen X, Smith JJ, Washington MK, Hill KE, Coburn LA, Peek RM, Chaturvedi R, Wilson KT, Burk RF, Williams CS.

Cancer Res. 2013 Feb 1;73(3):1245-55. doi: 10.1158/0008-5472.CAN-12-3150. Epub 2012 Dec 5.

16.

BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma.

Williams CS, Zhang B, Smith JJ, Jayagopal A, Barrett CW, Pino C, Russ P, Presley SH, Peng D, Rosenblatt DO, Haselton FR, Yang JL, Washington MK, Chen X, Eschrich S, Yeatman TJ, El-Rifai W, Beauchamp RD, Chang MS.

J Clin Invest. 2011 Oct;121(10):4056-69. doi: 10.1172/JCI44228. Epub 2011 Sep 12.

17.

MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model.

Barrett CW, Fingleton B, Williams A, Ning W, Fischer MA, Washington MK, Chaturvedi R, Wilson KT, Hiebert SW, Williams CS.

Cancer Res. 2011 Feb 15;71(4):1302-12. doi: 10.1158/0008-5472.CAN-10-3317. Epub 2011 Feb 8.

18.

Constitutive ERK MAPK activity regulates macrophage ATP production and mitochondrial integrity.

Monick MM, Powers LS, Barrett CW, Hinde S, Ashare A, Groskreutz DJ, Nyunoya T, Coleman M, Spitz DR, Hunninghake GW.

J Immunol. 2008 Jun 1;180(11):7485-96.

19.

Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17.

Monick MM, Powers LS, Hassan I, Groskreutz D, Yarovinsky TO, Barrett CW, Castilow EM, Tifrea D, Varga SM, Hunninghake GW.

J Immunol. 2007 Aug 1;179(3):1648-58.

20.

Active ERK contributes to protein translation by preventing JNK-dependent inhibition of protein phosphatase 1.

Monick MM, Powers LS, Gross TJ, Flaherty DM, Barrett CW, Hunninghake GW.

J Immunol. 2006 Aug 1;177(3):1636-45.

21.

Interventions for vitiligo.

Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003263. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD003263.

PMID:
16437451
22.

Picking up the tab for erythropoietin.

Kopelman PG, Barrett CW.

BMJ. 1991 Jun 1;302(6788):1335-6. No abstract available.

23.

Interpretation and management of PACT (prescribing analysis and cost) data on formularies.

Anderson ML, Barrett CW, Kopelman PG.

BMJ. 1990 Sep 8;301(6750):492. No abstract available.

24.

Districts' use of thrombolytic agents.

Burrell CJ, Skehan JD, Cowley ML, Barrett CW, Mills PG.

BMJ. 1990 Jan 27;300(6719):237-8. No abstract available.

25.

Transdermal absorption of fentanyl and sufentanil in man.

Sebel PS, Barrett CW, Kirk CJ, Heykants J.

Eur J Clin Pharmacol. 1987;32(5):529-31.

PMID:
2957211
26.

Design and preparation of a formulary--guide to the prescribing of medicines.

Tugwell AC, Thurston DR, Barrett CW.

J Clin Hosp Pharm. 1984 Dec;9(4):311-9.

PMID:
6526950
27.

Extemporaneous dilutions of proprietary topical corticosteroid preparations.

Kirsch JM, Gibson JR, Darley C, Barrett CW.

Dermatologica. 1982 Jul;165(1):71-2. No abstract available.

PMID:
7117653
28.

Problems presented by components of drug vehicles.

Rogers ML, Barrett CW.

J Hum Nutr. 1976 Feb;30(1):41-5. No abstract available.

PMID:
1026771
29.

Hospital pharmacy committees in England: Their structure, function, and development.

Brown AW, Barrett CW, Herxheimer A.

Br Med J. 1975 Feb 8;1(5953):323-5.

30.

The effect of particle size and vehicle on the percutaneous absorption of fluocinolone acetonide.

Barrett CW, Hadgraft JW, Caron GA, Sarkany I.

Br J Dermatol. 1965 Nov;77(11):576-8. No abstract available.

PMID:
5853251
31.

The role of vehicles in the percutaneous absorption of corticosteroids. An experimental and clinical study.

Sarkany I, Hadgraft JW, Caron GA, Barrett CW.

Br J Dermatol. 1965 Nov;77(11):569-75. No abstract available.

PMID:
5322445
32.

THE INFLUENCE OF VEHICLES ON SKIN PENETRATION.

BARRETT CW, HADGRAFT JW, SARKANY I.

J Pharm Pharmacol. 1964 Dec;16:SUPPL:104-7T. No abstract available.

PMID:
14265919
33.

A METHOD FOR APPLYING STANDARD QUANTITIES OF OINTMENT TO THE SKIN. PRELIMINARY AND SHORT REPORT.

BARRETT CW, HADGRAFT JW, SARKANY I.

Br J Dermatol. 1964 Nov;76:479. No abstract available.

PMID:
14213042
34.

Errors and evils of episiotomy.

BARRETT CW.

Am J Surg. 1948 Sep;76(3):284. No abstract available.

PMID:
18880307
35.

A complete pelvic floor laceration six and one-half month's pregnancy.

BARRETT CW.

Ill Med J. 1948 Feb;93(2):110-2. No abstract available.

PMID:
18857015
36.

Anatomy and embryology of the anus in relation to the pelvic floor.

BARRETT CW.

J Int Coll Surg. 1947 May-Jun;10(3):308-17. No abstract available.

PMID:
20256711
37.

A study of anatomy, embryology and function of the anus in relation to the caudal wall.

BARRETT CW.

J Natl Proctol Assoc. 1947 Jan-Feb;19(5-6):52-4. No abstract available.

PMID:
20247811
38.

A study of the construction, impairment and reconstruction of the pelvic floor.

BARRETT CW.

J Mich State Med Soc. 1946 Jul;45:899-913. No abstract available.

PMID:
20992897
39.

The important dividing wall between caudal herniation and prolapse of abdominal or pelvic viscera.

BARRETT CW.

West J Surg Obstet Gynecol. 1946 Jul;54(7):279-87. No abstract available.

PMID:
20992248
40.

The important dividing wall between caudal herniation and prolapse of abdominal or pelvic viscera.

BARRETT CW.

Proc Inst Med Chic. 1946 Mar 15;16:107. No abstract available.

PMID:
21066056
41.

Important dividing wall between caudal herniation and prolapse of abdominal or pelvic viscera.

BARRETT CW.

Am J Surg. 1946 Feb;71:167-71. No abstract available.

PMID:
21011653
42.

Advocates immediate replacement of uterus.

BARRETT CW.

Med World. 1946 Jan;64:18-25. No abstract available.

PMID:
21011344
43.

V. A new Technique for Dealing with the Appendix Stump.

Barrett CW.

Ann Surg. 1908 Feb;47(2):246-8. No abstract available.

Supplemental Content

Loading ...
Support Center